Search

Your search keyword '"David Lavi"' showing total 25 results

Search Constraints

Start Over You searched for: Author "David Lavi" Remove constraint Author: "David Lavi" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
25 results on '"David Lavi"'

Search Results

1. Remote immune processes revealed by immune-derived circulating cell-free DNA

2. Impairments of interpersonal synchrony evident in attention deficit hyperactivity disorder (ADHD)

3. Changing Preference of One- Vs. Two-Stage Implant Placement in Partially Edentulous Individuals: An 18-Year Retrospective Study

4. Group G Streptococcal Bacteremia in Jerusalem

5. Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events

6. S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

7. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

8. P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

10. P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

11. Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

12. Implementation of an organizational infrastructure paediatric plan adapted to bronchiolitis epidemics

13. P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

14. T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

15. Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer

16. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

17. Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma

18. #informetwitter: análisis cualitativo del usuario avanzado de la red social

19. Temperature Field Progression in Annular Tube Around Heated Rod in Respect to the Mass Flow of Coolant

Catalog

Books, media, physical & digital resources